MapLight Therapeutics (MPLT) Enterprise Value (2024 - 2026)
MapLight Therapeutics (MPLT) posted Enterprise Value of -$711.5 million for Q4 2025, down 213.19% sequentially from -$227.2 million in Q3 2025, and down 553.96% YoY from $156.7 million in Q4 2024.
MapLight Therapeutics (MPLT) Enterprise Value (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported Enterprise Value for 2 years, with the latest figure at -$711.5 million in Q4 2025.
- Quarterly Enterprise Value fell 553.96% year-over-year to -$711.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$711.5 million (down 553.96% YoY) and the FY2025 annual result came in at -$711.5 million, down 553.96% from the prior year.
- Enterprise Value retreated to -$711.5 million in Q4 2025 per MPLT's latest filing, from -$227.2 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$108.8 million in Q4 2024 and troughed at -$711.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | MapLight Therapeutics | 533.88 Mn | 533.88 Mn | - | -304.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -304.73 Mn |
| Dec 31, 2025 | -711.47 Mn |
| Sep 30, 2025 | -227.17 Mn |
| Dec 31, 2024 | -108.80 Mn |